PYC THERAPEUTICS LIMITED

0.42%

$1.20

Market Cap $696.9M

Healthcare Biotechnology

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company... PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.More

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting...

Latest Threads

Tag

Subject

PYC

Ann: Presentation of Clinical Proof of Concept in Lead Program

15:40

7.3K

15:40

Last post hottod

7.3K

PYC

Cannacord research conclusion today

15:21

1.1K

15:21

Last post hottod

1.1K

PYC

Ann: Change in substantial holding

28/04/25

346

28/04/25

Last post

ASX News

346

PYC

Ann: Quarterly Activities/Appendix 4C Cash Flow Report

26/04/25

2.1K

26/04/25

Last post travelbug2

2.1K

PYC Biotech

PYC Chart and Technical Analysis

3 4 5

24/04/25

284

156K

24/04/25

Last post Ladytradr

284

156K

PYC

PYC - General Discussion

14 15 16

24/04/25

946

482K

24/04/25

Last post Boomer55

946

482K

PYC

Ann: Application for quotation of securities - PYC

23/04/25

356

23/04/25

Last post

ASX News

356

PYC

Ann: First Subject Dosed in PKD Clinical Trial

23/04/25

13K

23/04/25

Last post prigozhinsghost

13K

See All Discussions

Timeline

Change in substantial holding
28 Apr 16:33	Share

Presentation of Clinical Proof of Concept in Lead Program
28 Apr 09:02	Share

Quarterly Activities/Appendix 4C Cash Flow Report
24 Apr 08:48	Share

Application for quotation of securities - PYC
23 Apr 17:44	Share

Completion of Entitlement Offer
17 Apr 08:35	Share

First Subject Dosed in PKD Clinical Trial
10 Apr 08:45	Share

Placement of Shortfall
09 Apr 09:45	Share

Investor Webinar Presentation
28 Mar 09:17	Share

Application for quotation of securities - PYC
21 Mar 09:40	Share

Q1 Investor Webinar 28 March 2025
21 Mar 09:38	Share

Completion of Retail Entitlement Offer
18 Mar 14:19	Share

Change of Director's Interest Notice
27 Feb 18:43	Share

Ceasing to be a substantial holder
27 Feb 16:22	Share

Half Yearly Report and Accounts
27 Feb 16:16	Share

Application for quotation of securities - PYC
26 Feb 10:45	Share

Despatch of Notice to Ineligible Retail Shareholders
24 Feb 12:12	Share

Despatch of Retail Offer Document
24 Feb 12:10	Share

Retail Entitlement Offer Booklet
24 Feb 12:09	Share

Completion of Institutional Entitlement Offer
19 Feb 09:45	Share

Cleansing Notice Under Section 708AA
17 Feb 10:01	Share

Proposed issue of securities - PYC
17 Feb 10:00	Share

PYC Equity Raising Presentation
17 Feb 09:58	Share

PYC Equity Raising to Raise up to $146 Million
17 Feb 09:57	Share

Trading Halt
17 Feb 09:42	Share

Approval to Commence Human Trials in Kidney Program
10 Feb 08:51	Share

Notification of cessation of securities - PYC
03 Feb 16:46	Share

ADOA Safety Review Committee Approves Dose Escalation
31 Jan 09:32	Share

Quarterly Activities/Appendix 4C Cash Flow Report
29 Jan 09:25	Share

US FDA Grants Rare Pediatric Disease Designation to VP-001
20 Jan 09:36	Share

PYC Nominates Fourth Clinical Drug Candidate in PMS Program
16 Dec 09:16	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.20		Change -0.005(0.42%)		Mkt cap ! $696.9M

Open	High	Low	Value	Volume
$1.21	$1.24	$1.18	$222.9K	184.0K

Buyers (Bids)

No.	Vol.	Price($)
2	1528	$1.20

Sellers (Offers)

Price($)	Vol.	No.
$1.23	25000	1

View Market Depth

No.	Vol.	Price($)
2	1528	1.195
1	1229	1.190
1	1229	1.185
2	34623	1.170
1	4310	1.160

Price($)	Vol.	No.
1.225	25000	1
1.230	1229	1
1.235	1229	1
1.240	63776	3
1.250	14534	2

Last trade - 16.10pm 29/04/2025 (20 minute delay)


Last $1.21		Change -0.005 ( 2.54 %)
Open	High	Low	Volume
$1.19	$1.24	$1.18	22955
Last updated 15.43pm 29/04/2025 ?

PYC (ASX) Chart

PYC THERAPEUTICS LIMITED

Latest Threads

High Value Titanium Mineral Assemblage Confirmed

Timeline

Featured News

Latest Videos

PYC Therapeutics (ASX:PYC) lands FDA clearance for first human trials of RP11 treatment drug

06 Mar 2023 13:04 (AEDT)

Latest Articles

PYC Therapeutics jumps just shy of +4% as second-stage blindness drug study greenlit

PYC Therapeutics (ASX:PYC) has jumped on Friday as it moves on the the next stage of its escalating single-dose study using its drug PYC-001 to treat a genetic children’s disease causing blindness.(Most gains, however, were quickly sold off.)Autosomal Dominant Optic Atrophy (ADOA)...

Scientific conference spotlights PYC's work on blindness disease treatment

PYC Therapeutics Ltd will have data from its ongoing trial into a drug candidate to treat Retinitis Pigmentosa type 11 presented in Singapore

PYC Therapeutics moves into final stage of child blindness study

PYC has been approved to escalate doses of its drug candidate VP-001, treating Retinitis Pigmentosa 11, in a second patient cohort.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News